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IVIanagement of Extramedullary Plasmacytomas
James A. Bonner, MD,* Jadranka Dragovic, MD,^ and Michael P. Abrash, MD*

From 1965 through 1982. 12 patients with solitary, biopsy-proven extramedullary plasmacytomas
(EMPs) were treated at our institution with surgery alone or biopsy followed by radiation therapy. The
median age of the patients was 67 years, and the median-follow-up was 58 months. Of the seven
patients who were treated by primary surgery, three developed recurrent or distant disease. Five
patients underwent biopsy followed by radiation therapy, and none of their tumors progressed. Our
series and a review ofthe literature show that occasionally EMPs will incompletely regress even after
high doses of radiation (greater than 65 Gy): however, we recommend that doses of45 to 50 Gy be used
for most tumors, with greater doses being reservedfor bulky or inaccessible tumors. Each tumor was
classified histologically as well differentiated, moderately differentiated, or poorly differentiated.
Patterns of pathology appear to be ofno prognostic significance. Five patients (42%) were noted to
have second neoplasms. (Henry FordHosp MedJ 1987:35:245-50)

xtramedullary plasmacytomas (EMPs) are rare plasma cell
neoplasms that occur in the soft tissues outside of the skeletal system. In a study from the Birmingham Regional Cancer
Registry, the cmde annual incidence rate for EMPs was 0.04 per
100,000 people as compared to 1.9 per 1(X),000 for medullary
plasma cell tumors (1). The incidence of EMPs in relation to
multiple myeloma was 1:40. In a large review of 228 cases of
EMPs by Wiltshaw (2), 76% of EMPs presented in the upper air
passages, 6% in the lower air passages, 4% in lymph nodes and
spleen, 3% in the gastrointestinal tract, 3% in the thyroid, 1%
in the testes, and 4% in other sites. Presenting symptoms correspond to the tumor locarion and often include dysphagia,
hoarseness, stridor, and a lump in the throat, and less often include lymph node enlargement, cutaneous lesions, abdominal
pain, or gastrointestinal bleeding (2-14).
EMP is defined as a biopsy-proven plasma cell tumor in one
or two extraskeletal foci without evidence of disease following
bone marrow and radiological evaluation of the skeletal system
(1,15,16). In Wiltshaw's series (2), 33% to 40% of patients with
EMPs developed disseminated disease (metastatic spread beyond lymph node involvement), with those tumors which had
recurred locally having the higher rate of dissemination and, in
contrast, the majority of solitary plasmacytomas of bone having
progressed to multiple myeloma. Wiltshaw (2) suggested that
solitary plasmacytomas of bone are indeed an early manifestation of multiple myeloma, whereas EMPs represent a separate
clinical entity.
Numerous studies have established that surgery, radiation
therapy, or a combination of these treatments represent appropriate management of EMPs (2-10,13,17-24). Local control
rates of 60% to 80% have been reported (2-10,13,17-24). This
study reviews the pathology, treatment, and clinical course of 12
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patients with biopsy-proven EMPs that were diagnosed at Henry
Ford Hospital from 1965 to 1982.

Materials and Methods
Twelve cases of biopsy-proven EMPs were seen at Henry Ford
Hospital from January 1,1965, to December 31,1982. This endpoint was selected to allow for a minimum of four years of follow-up of all patients.
All cases of biopsy-proven EMPs were identified through the
computerized file of Hemy Ford Hospital's pathology department. Cases were included in the study if the following criteria
were met: 1) extraskeletal plasma cell tumor proven by biopsy
with no more than two foci, 2) normal bone marrow with less
than 10% plasmacytosis, and 3) no evidence of bony metastasis
on skeletal x-rays. All diagnostic evaluations included serum
protein electrophoresis. Patients were included regardless of
their M protein status. One patient was excluded from the study
because no bone marrow biopsy was performed.
The pathology slides were reviewed in each case with a Henry
Ford Hospital pathologist. Cases were identified as true plasmacytomas by the methods outlined by Batsakis (25). Three
cases, which were considered plasmacytomas at tbe time of diagnosis, were excluded from the study because a review of the

Submitted for publication: July 20, 1987.
Accepted for publication: October 9, 1987.
•Formerly Department of Intemal Medicine, Henry Ford Hospital. Currently Department of Radiation Oncology, The University of Michigan Hospital, Ann Arbor
tDepartment of Therapeutic Radiology, Henry Ford Hospital.
tDepartment of Pathology. Division of Anatomic Pathology, Henry Ford Hospital.
Address correspondence to Dr. Bonner, Department of Radiation Oncology, The University of Michigan Hospital, 1500 E Medical Center Drive, Room B2C490/00I0, Ann Arbor,
MI 48109-0010.

Extramedullary Plasmacytomas—Bonner et al

245

Fig 1—Well-differentiated cutaneous plasmacytoma ofthe posterior axillary line (case 3) (hematoxylin-eosin stain, XlOO).

Fig 2—Poorly differentiated plasmacytoma ofthe thyroid gland
(case 10) (hematoxylin-eosin stain. XlOO).

histology showed that plasma cell granuloma could not be mled
out. After these exclusions, a total of 12 patients were included
in the study. The pathology of each tumor was graded by
the method of Kapadia et al (26) as well differentiated (mature plasma cells with uniform size [Fig 1]), moderately differentiated (larger nuclei with less peripheral chromatin clumping
and less abundant cytoplasm), and poorly differentiated (large
pleomorphic nuclei with scant cytoplasm [Fig 2]). Unfortunately, surgical margins could not be adequately assessed retrospectively.
All cases were treated by surgery, radiation therapy, or a combination of these treatments. All cases include follow-up to the
present time or to the patient's death. Case 4 was previously
reported in the literature without follow-up (11).

10:2. Follow-up ranged from three to 242 months following initial treatment. The median follow-up time was 58 months.
For this series of patients with EMPs, the site of presentation
was the upper airway in 33% (four cases), the thyroid in 17%
(two cases), a cutaneous lesion in 17% (two cases), and one case
each in the spleen, the prostate, a posterior cervical node, and a
hilar lymph node. The presenting symptoms were related to the
site of the primary tumor Patients with upper airway EMPs had
symptoms of nasal obstruction, sore throat, and hoarseness.
Both patients with thyroid EMPs presented with enlarging neck
masses, and one patient also complained of dysphagia. One patient with a cutaneous EMP presented with a breast mass, and
the other patient presented with a draining ulceration ofone year
duration. The patient with a left hilar lymph node EMP presented with a mass on chest x-ray, and the patient with a cervical
lymph node EMP presented with a posterior neck mass. The patient with a prostatic EMP presented with urinary obstruction,
and the patient with a splenic EMP presented with a traumatic
splenic tear following an automobile accident.

Results
Table 1 outlines the clinical presentation, treatment, course,
and pathological classification of EMP for each of the 12 patients
in this study. Age at presentation ranged from 44 to 88 years,
with a median age of 67 years. The ratio of males to females was
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M protein was present in three cases. In two ofthese cases, the
M protein was present at the time of diagnosis. In one case (case
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Table 1
Course of Patients with Extramedullary Plasmacytomas
^ge (years )/race/sex
piagnosis (month/year)
Site

Bone marrow
Other tumor

• 'S:

^

Presenting symptom
M protein
Tteatment

H
f
Result

•4' * '•
A-

Case I
71/W/F
1962
Left nasal vestibule

Case 2
44/W/M
10/65
Posterior cervical
lymph node

Case 3
56/B/M
7/67
Cutaneous lesion.
posterior axillary
line

Negative, 1%
plasmacytosis
Basal cell cancer
1970, acute
leukemia 1974
Left nostril
obstruction
Negative
Surgically resected
twice (1962,
1966); 8/67
recurred, 3,000
rads/21 days;
12/69 recurred.
3,000 cGy/21
days; 2/72
recurred, 3,600
cGy/21 days
Died 12/74 of
myocardial
infarction, acute
myeloblastic
leukemia

Negative

Negative, 1.2%
plasmacytosis
None

Follicular cancer of
thyroid, kidney
cancer(2/66)
Posterior neck mass
Positive
10/65 surgically
resected

Died 2/66 of
pulmonary
embolus with
evidence of
multiple
myeloma
Well differentiated

Miology

Well differentiated

Age (years)/race/sex
Diagnosis (month/year)
Site

Case 7
53/B/M
9/75
Spleen

Case 8
66/W/M
5/79
Left tonsil and left
nasopharayx

Bone marrow

Negative

Other tumor

None

Negative, 1.5%
plasmacytosis
None

Presenting symptom

Splenic tear
following car
accident
Negative
9/75 surgically
resected

f

M protein
•Deatment

Result
Pathology

Case 5
77/B/M
7/75
Prostate

Case 6
61/W/M
8/75
Left hilar lymph
node
Negative

None

Negative, 5.6%
plasmacytosis
None

Right breast mass

Urinary obstruction

Negative
11/68 breast mass
resected; 4/69
right axillary
mass resected;
2/70 right
axillary recurred.
2,200 cGy/14
days

Negative
7/75 transurethral
resection prostate

Appeared on chest
x-ray
Negative
8/75 surgically
resected

No clinical evidence Died 4/72 of
of disease 9/87
myocardial
infarction, no
clinical evidence
of disease

Died 10/78 of
myocardial
infarction, no
clinical evidence
of disease

Died 10/81 of
myocardial
infarction, no
clinical evidence
of disease

Well differentiated
(Fig. I)
Case 9
66/W/M
2/80
Laryngeal mass at
anterior
commissure
Negative, 2%
plasmacytosis
Transitional cell
cancer of bladder
2/80

Moderately

Moderately
differentiated
Case 12
67/B/M
10/82
Nasophamyx

Draining lesion for
one year
Negative
7/67 surgically
resected

Sore throat radiating Hoarseness
to ear X 21 days
Negative
5/79 excisional
biopsy followed
by 4,400
cGy/35 days

Positive
2/80 excisional
biopsy followed
by 5,000
cGy/34 days

Died 12/75 of sepsis No clinical evidence Died 12/86 of
of disease 9/87
pneumonia
Moderately
Poorly
Poorly
differentiated
differentiated
differentiated

9) semm electrophoresis was not performed until two years after
the diagnosis, and at that time it was positive. (The quantitative
Values for immunoglobulin were normal at diagnosis and remained normal two years later.) Of tbe cases with positive M
protein at diagnosis, one developed multiple myeloma in three
months, one died of unrelated causes in two months, and one has
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Case 4
76/W/M
11/68
Right cutaneous
breast mass.
right anterior
axillary mass
Negative

Moderately
dilTercntiatcd
('ase 10
88/W/M
11/80
Thyroid and
adjacent lymph
nodes and muscle
Negative
None

Dysphagia and
neck mass
X 5 months
Positive
11/80 total
thyroidectomy
followed by
4,000cGy/3I
days
Died 1/81 of
pneumonitis
Poorly
differentiated
(Fig 2)

Case 11
75/W/F
5/81
Thyroid
Negative, 2%
plasmacytosis
Adenocarcinoma of
lung surgically
excised 2/79
Enlarging neck
mass
Negative
5/81 needle biopsy
followed by
5,000 cGy with
1,000 cGy
reduced field
boost over
60 days
No clinical evidence
of disease 9/87
Poorly
differentiated

None

Negative, 6%
plasmacytosis
Simultaneous
squamous cell
cancer of oralphamyx with
metastasis to neck
Sore throat
Negative
Excisional biopsy
followed by
2,200 cGyto
tumor at our
institution, and
3,200 cGy at
outside hospital
Died 3/83 of
squamous cancer
Moderately
differentiated

no evidence of disease after seven years (continues to have M
spike). No correlations were made between M protein and survival because of the small sample size.
Seven of the 12 patients had primary surgical therapy. Three
tumors recurred: one locally after four years, one metastasized
to regional lymph nodes at four months, and one progressed to
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Table 2

lithology
Well differentiated
Moderately
differentiated
Poorly
differentiated

Total No.
of Patients
3

No. of
Patients with
M Protein
1

No. of
Local
Recurrences
1

5

0

1

1

0

4

2

0

1

0

multiple myeloma at three months. The remaining four patients
were disease-free at the last follow-up visit. One patient (case 1),
in whom a local recurrence developed in 1966 following a surgical resection ofher nasal tumor in 1962, had a second surgical
excision of tumor in 1966. She was referred to our institution
in 1967 when she had a second recurrence of tumor Her course
at Henry Ford Hospital included three recurrences in 1967,
1969, and 1972, and these episodes were treated with radiation
doses of 3,000 cGy, 3,000 cGy, and 3,600 cGy, respectively.
She died of acute myeloblastic leukemia in 1974, with no clinical evidence of multiple myeloma; however, her nasal tumor
never completely regressed following her last radiation dose in
1972. (She refused to consider any further treatment.) Another
patient (case 4) developed a regional (right axillary) lymph node
metastasis following the initial surgical resection of his right
breast mass. He subsequently underwent an excisional biopsy of
this anterior axillary lymph node recurrence. His axillary node
mass recurred in 1970, and he received radiation therapy to
the involved areas (2,200 cGy/16 days). He was free of disease
when he died of a myocardial infarction almost four years after
presentation. Another patient (case 2) was noted to have multiple myeloma at autopsy three months following surgical resection of his posterior cervical lymph node EMP. He died of a
pulmonary embolus, and the bone marrow at autopsy, although
negative at the time of diagnosis, was consistent with multiple
myeloma.
The group of patients treated primarily by surgery included
two unusual cases: a prostatic EMP, and an EMP involving a left
hilar lymph node. The patient who developed prostatic EMP
presented with urinary obstruction and was found to have an
enlarged prostate on physical examination. He underwent a
transurethral resection of his prostate, and plasmacytoma was
diagnosed. He died 39 months after diagnosis with no clinical
evidence of disease. The other patient, whose left hilar lymph
node EMP was discovered on chest x-ray, underwent a thoracotomy with removal of the involved lymph node. No extension
of tumor was noted at surgery. This patient died of a myocardial
infarction more than six years after diagnosis with no clinical
evidence of disease.
Five patients in this study were initially treated with biopsy
followed by radiation therapy. Four of these patients had excisional biopsies, and one had a needle biopsy. None of the tumors
recurred locally or progressed to multiple myeloma. The patients received doses of radiation therapy ranging from 4,000
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No. of
Patients
Developing
Multiple
Myeloma
1

No. of
Patients with
Lymph Node
Involvement
0

cGy/31 days to 6,000 cGy/60 days. The average follow-up for
thesefivecases was 53 months.
As noted, each tumor was classified according to its histological differentiation. Three tumors were classified as well differentiated,fiveas moderately differentiated, and four as poorly
differentiated (Table 2). Information regarding the number
of patients in each histological category with M protein, locally
recurrent disease, progression to multiple myeloma, and node
involvement is presented in Table 2.
A total of 42% of patients (five cases) had other cancers in
addition to their EMP. These second neoplasms included acute
myeloblastic leukemia, follicular cell carcinoma of the thyroid,
transitional cell carcinoma of the bladder, adenocarcinoma of
the lung, and squamous cell carcinoma of the head and neck.
The second neoplasm was discovered synchronously with the
EMP in two cases (cases 9 and 12), prior to the diagnosis of EMP
in one case (case 11), and following the diagnosis of EMP in two
cases (cases 1 and 2). None of these second neoplasms fell in the
portal of treatment.

Discussion
Many reports have commented on appropriate treatment of
EMPs. Surgery, radiation therapy, or a combination of these
treatments have proven to be efficacious in various series
(2-10,13,17-23). Following appropriate management, it remains
unclear as to which tumors will recur locally or progress to disseminated disease. Progressive increase in M protein, bone destmction, local recurrence, and unusual site of presentation have
been indicated as significant prognostic factors regarding decreased survival or eventual development of multiple myeloma
(1,2,8,21). The presence of M protein on semm electrophoresis
and lymph node involvement have not shown prognostic significance (2,8,21). These prognostic factors were not evaluated in
our study because of the small population.
In a review of 272 cases from the Royal Marsden Hospital and
other institutions, Wiltshaw (2) established that the rate of local
recurrence for EMPs was similar for surgery (40%) or radiation
therapy (34%) as primary treatments. Radiation doses were not
specified in Wiltshaw's study. It was also evident that combined
treatment (surgery and radiation therapy) resulted in fewer local
recurrences (16%) than either single treatment alone. Disseminated disease occurred in 35% of all cases and was unrelated to
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tjie mode of therapy. In our series, five cases (cases 8-12) were
originally treated with radiation therapy (either as primary treatjnent or in combination with surgery), and none of the tumors
progressed. Of the seven cases originally treated with surgery,
one patient's tumor failed locally after four years and was subsequently resistant to several attempts of surgery and radiation
therapy (case 1), one patient developed a regional lymph node
metastasis which required surgical resection in 1969 and subsequent radiation therapy in 1970 (case 4), and one patient went on
to develop multiple myeloma at three months (case 2). Case 2
was most likely a case of multiple myeloma which presented as a
soUtary lesion. In our small series it is difficult to make any conclusions about the benefits or risks of surgery versus radiation
therapy; however, consideration of Wiltshaw's (2) data leads to
the recommendation that radiation therapy be given following
surgical excision of EMPs. Conversely, surgical excision should
be considered for residual tumor following primary radiation
therapy.
The radiosensitivity of EMPs has been given much consideration in the literature. Harwood et al (21) evaluated 23 cases of
EMP and recommended that a dose of 3,500 cGy in three weeks
be given for good local control and a low rate of disseminated
disease. Corwin and Lindberg (8) recommended doses of 4,000
to 5,000 cGy. Mendenhall et al (23) reported a review of the literature of 81 patients with solitary plasmacytomas (skeletal and
soft tissue) and noted a significant improvement in local control
rates at doses above 4,000 cGy. Local failures occurred in 6% of
pafients with doses greater than 4,000 cGy and in 31% for doses
less than 4,000 cGy. Mill and Griffith (22) analyzed 43 patients
(16 patients from their institution and 27 patients from the literature) with plasmacytomas of bone and soft tissues (22 cases
were EMPs). They recommended doses of 5,500 to 6,000 cGy
over six weeks for the EMPs. However, they also recognized that
local failures occurred in the EMPs up to a dose of 6,750 cGy
and noted that their statistics were based on a small number of
cases. In a series of EMPs by Bush et al (4), local disease was
noted in one of their ten cases following a dose of 6,075 cGy/41
days. In our series the nasal tumor of case 1 recurred following
two surgical resections, and the patient subsequently received
radiation doses of 3,000, 3,000, and 3,600 cGy at approximately two-year intervals. Tumor was still present on physical
examination at the end of treatment, and the patient refused further therapy. Five other cases in our series received radiation
therapy in doses ranging from 4,000 cGy/31 days to 6,000
cGy/60 days with no local failure or dissemination of disease.
All of the aforementioned series suggest that EMP tumors occasionally will incompletely regress even with high doses of radiation. However, we recommend that doses of 4,500 to 5,000 cGy
over three to five weeks be given for adequate local control of
Host tumors and that greater doses may be necessary to irradicate bulky or inaccessible tumors (case II).
Knowling et al (18) reported the University of Toronto experience with EMPs and found that seven of 25 cases of EMP presented with lymph node involvement. Also, regional lymph
nodes were the initial site of relapse in three other patients.
In our series, case 4(11) was the only case with regional lymph
Oode metastasis. As noted, this patient presented with a subareolar breast mass plasmacytoma, which initially was sur-

'tenry Ford Hosp Med J—Vol 35, No 4, 1987

gically resected and subsequently recurred in a right anterior
axillary lymph node two months after diagnosis. This recurrence responded to surgical resection and radiation, and no evidence of disease was present at the time of death 41 months after
presentation. In the Toronto series (18) all three patients who developed node metastases following treatment to the primary site
died with evidence of tumor In their study, Knowling et al raised
the question of whether prophylactic regional lymph node irradiation should be instituted at the time of initial treatment. This
question needs to be further investigated to determine if added
benefits exist for early treatment of regional lymph nodes.
Several studies have reviewed the pathology of plasmacytomas (25-29), and Batsakis and colleagues (25,29) concluded-that histological appearance cannot be used as a reliable
indicator of biological activity. This conclusion is corroborated
by our series, in which two tumors showed aggressive biological
behavior (one local recurrence and one progression to multiple
myeloma), and both were well differentiated by the criteria
noted previously. Two of the four patients whose tumors were
poorly differentiated are still living after six to eight years of follow-up. One patient died of pneumonitis, and another died of
pneumonia. Neither patient showed evidence of a plasmacytoma recurrence at the time of death. Our data showed no correlation between pathology and biological behavior of tumor;
however, it is apparent that well-differentiated tumors can lead
an aggressive course.
Also corroborated by this series is the association of plasmacytomas with other carcinomas, which has been documented
in several reports (29-32). In an autopsy series, Weitzel (33)
noted that the coexistence of other carcinomas with plasma cell
neoplasms was markedly higher (19.3%) than the incidence of
carcinoma associated with lymphoma/leukemia (7.96%) or the
incidence of multiple primary carcinoma (4.2%). In our series,
42% of patients had evidence of other malignancies during their
lifetime. Hosley (31) hypothesized that plasma cell neoplasms
and second cancers in one patient could have a common etiological factor, such as an inherited defect, or a common carcinogen. He also suggested that plasma cell neoplasms in the presence of other cancers may represent a plasma cell hyperplastic
response which has undergone malignant transformation. In his
series it was unusual to find both the plasma cell neoplasm and
the second carcinoma to be widely disseminated in a single patient. Usually one process remained localized while the other
process disseminated. Therefore, it is possible that patients will
be adequately cured of their EMP only to encounter a battle with
a second neoplasm.
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